Preprints.org

Article

Radiation Sensitivity and Efficacy in Aggressive and Non-Aggressive Basal Cell Carcinoma (BCC) of the Skin

Lio Yu , Michael Kaczmarski , Peyton Harris [*] , Clay Cockerell

Article

Radiation Sensitivity and Efficacy in Aggressive and Non-Aggressive Basal Cell Carcinoma (BCC) of the Skin

Running Heading: IGSRT Sensitivity and Efficacy in High Risk and Non High Risk Basal Cell Carcinoma

Lio Yu [1], Michael Kaczmarski [2], Peyton M. Harris [3],* and Clay Cockerell [4]

[1] Chief of Radiation Oncology, Laserderm Dermatology, Smithtown, NY; Research Chair, Dermatology Association of Radiation Therapy

[2] Medical University of Warsaw, Poland

[3] Texas A&M College of Medicine, Dallas, Texas

[4] Clinical Professor of Dermatology and Pathology; UT Southwestern Medical Center; Chair, DFW/Lake Granbury Dermatology Residency Program, Dallas, Texas

* Correspondence: peyton.harris@tamu.edu

Abstract: Background: High risk (HR) basal cell carcinoma (BCC) subtypes have been associated with high recurrence rates that is felt to be better managed surgically. Specifically, Mohs Micrographic Surgery (MMS) has been considered most effective for aggressive HR BCCs and superior to traditional nonsurgical techniques, including radiation. Recently, superficial radiation therapy with high resolution ultrasound image guidance called Image Guided Superficial Radiation Therapy (IGSRT) displayed high local control (LC) rates and is becoming established as an excellent non-surgical alternative to MMS for non-melanoma skin cancer (NMSC). **Objectives:** We present one of the largest experiences in the USA on treatment of only "pure" BCCs using IGSRT and specifically evaluate if there are differences in LC between HR BCC versus non-HR subtypes using this technology. **Methods:** A retrospective analysis was conducted on 8,524 purely BCC lesions treated with IGSRT in the continental United States. We compared the results of BCCs treated with IGSRT separated by HR vs non HR groups including 394 HR BCC lesions and 8,130 non HR BCC lesions. High risk was defined as infiltrative, micronodular, morpheaform, and sclerosing subtypes. Non-HR BCC included superficial, nodular, and not otherwise specified (NOS) subtypes. Local control (LC) rates at two and five years were calculated with actuarial life-table and Kaplan-Meier methods and statistically compared using log rank tests. **Results:** IGSRT treatment of the HR BCC group showed no recurrences with two and five-year actuarial and KM LC rates all at 100%. In comparison, the non-HR BCC cohort achieved similar two and five-year actuarial LC rates of 99.7% and 99.2% (KM LC at 99.5% and 99.2%), respectively. No statistical differences in LC rates between the two cohorts (p=0.233 each) resulted. Patients tolerated treatment well with little or rare high grade RTOG toxicity reported in both cohorts. **Conclusion:** HR BCC may be treated just as effectively as low risk BCC using IGSRT and presents a viable alternative to MMS. The targeted approach using IGSRT, incorporating high resolution dermal ultrasound (HRDUS), appear to enhance treatment accuracy and effectiveness demonstrating high LC rates in all subtypes of BCC comparable to MMS and is an excellent non-surgical option.

Keywords: non-melanoma skin cancer; basal cell carcinoma; image guided superficial radiation therapy

Plain language summary:

Effectiveness of a non-surgical skin cancer treatment using an image guided form of radiation modality on all subtypes of basal cell skin cancer.

Recent studies using a non-surgical treatment combining low penetrance radiation with ultrasound called Image Guided Superficial Radiation Therapy (IGSRT) showed promise in curing Basal Cell Cancer (BCC) of the skin, which is the most common skin cancer worldwide afflicting millions annually. Recent studies on early stage (I, II) BCCs treated with IGSRT appear to rival the best surgical treatment available called Mohs Micrographic Surgery ("Mohs" or MMS). Furthermore, certain subtypes of BCC appear to behave more aggressively with worse outcomes even with surgery and is generally felt inappropriate for radiation treatment.

This study presents one of the largest experiences (using medical chart review) in approximately 8500 "pure" BCC cases treated by IGSRT across the continental United States separated by aggressive vs non-aggressive subtypes for early stages (I, II) as well as more advanced (stage III) BCC cases to evaluate the efficacy and safety.

This study confirms the high cure/control rate and safety of IGSRT for all subtypes of BCC which appear equivalent with Mohs (although the study was not meant to be a head to head comparison of the 2 different modalities). Moreover, the aggressive types of BCC showed similar (if not marginally better) cure rates than the more common non-aggressive BCC subtypes.

The potential benefits to patients from this study show there is now a clinically proven non-surgical treatment with the same effectiveness as surgery for the most common cancer on the planet.

Key Points

- This study provides evidence that backs up using IGSRT as a viable treatment option to MMS for both high risk and non-high risk BCC cases, achieving similar local control rates for both groups regardless of histologic aggressiveness.

- It highlights that high risk BCC is more sensitive to radiation therapies such as IGSRT than previously believed, challenging the conventional practice of surgical treatment.

1. Introduction

Skin cancer is the most common form of cancer globally and presents a significant health challenge with various subtypes and varying prognoses. Among the many kinds of cancers, basal cell carcinoma (BCC) emerges as the most common type, accounting for nearly 80% of non-melanoma skin cancers [1]. The incidence of non-melanoma skin cancers (NMSC) is increasing epidemically with an estimation of 3.5 million patients with 5.4 million lesions diagnosed annually in the United States as of 2012 and continues to rise [2]. The need for developing effective strategies to manage the disease is becoming more imperative, particularly in the context of BCC.

For early stage BCC, which is the most common skin cancer amongst patients, several approaches are available for these cases including surgical excision, radiotherapy, topical imiquimod, photodynamic therapy [3,4] and Mohs Micrographic Surgery (MMS). Nevertheless, after BCC treatments (surgical or non-surgical) there is an increased risk of future BCC developing with up to a 16% chance of the development of new BCCs within the first year after initial treatment and an expected 5 year incidence for BCC developing of 45% as compared to the general US white population [5] which demonstrates the scope of the problem.

Although basal cell carcinoma has a characteristic of slow progression, local invasiveness, and low metastatic potential, there exist histological subtypes that are considered "high risk" that have been observed to have a more aggressive nature and ability to recur [6]. Certain histologies such as morphemic, sclerosing, infiltrative, and micro nodular subtype present a challenge to typical treatment practices that have led to favoring surgical interventions over alternative modalities [7].

According to the American Academy of Dermatology (AAD), surgical interventions with Mohs micrographic surgery are widely recognized as the gold standard of care for patients with

morpheaform and sclerosing BCCs due to their ability to conserve healthy tissue and retain high cure rates [8]. Conventional wisdom in dermatological oncology has a long held the belief that high risk BCCs are less responsive to radiation therapy and less prone to recur with surgery.   This belief has been rooted by the inherent biological aggressiveness of these histologies backed by prior observational data [9]. Surgical management of high risk cases such as morpheaform BCC on the nose was observed to have an incomplete excision rate of 61.5% and at the ear of 50% [10]. Coupled with various concerns about the efficacy and safety aspects of radiation therapies, this has led to vigilant or cautionary approaches in treating these high risk BCC histologies. However, this established approach may not be suitable for all patients. Several factors such as disfigurement, the overall health of the patient, or the ability to tolerate surgery treatments may have an influence on treatment decisions. Thus, it is crucial to consider alternative and less invasive treatments in selected cases [11].

As radiation therapy techniques have advanced recently, the introduction of image-guided superficial radiation therapy (IGSRT) which is a combination of high resolution dermal ultrasound (HRDUS) with superficial radiation therapy (SRT) has allowed for the reconsideration of methods employed on treating skin cancer. Specifically, with regard to early stage NMSC (including high risk BCCs), IGSRT, which is regarded as precision and targeted medicine, potentially mitigates limitations associated with conventional non image-guided traditional radiation therapy (such as external/electron beam radiotherapy [XRT] and superficial radiation therapy [SRT]) and has been shown to statistically improve outcomes on treatment of all major histologies of NMSC, such as BCC, SCC and SCCIS [12–15]. On this basis, it stands to reason that re-assessment of the previous notion of bypassing the option of radiotherapy in high risk subtypes of BCCs should be evaluated using this more modern method of radiotherapy incorporating image guidance intrinsically to assess to see if the prevailing sentiment of non-radiation approach still holds true.

We set out to evaluate the differences, if any, in the local control rate of aggressive high risk BCC subtypes in comparison to the non-aggressive BCC subtypes treated with the use of this newer technology of IGSRT. A recent study including BCC and SCC of various subtypes and grades was published showing "equivalence" of excellent results using IGSRT in early stage I and II cases at 2 years, 4 years, and 6 years [16]. This present study selects only "pure" BCC case added from a New York clinic including stage T3 cases and calculates 5 year LC rates not available in other recent IGSRT publications [16–18].

2. Methods and Methods

From 2016-2023, pathologic proven BCCs of stage I, II,III (AJCC 8TH edition cancer staging with tumor stage T1, T2, and T3) treated w IGSRT at multiple institutions throughout the continental United States were retrospectively reviewed   and analyzed. Only pure BCCs without combined or collision histologic components (ie, without any squamous cell carcinoma (SCC), squamous cell carcinoma in situ (SCCIS), keratoacanthoma (KA), other non BCC histologies) were selected. We separated the high risk (HR) BCC histology cohort from the non-HR BCCs, gathered the lesion characteristics, treatment parameters and analyzed the rate of recurrence deriving the lesion local control post IGSRT treatment.   Lesion and patient characteristics were summarized descriptively. Actuarial (life-table) local control (LC) rate and Kaplan-Meier (KM) LC were calculated and plotted graphically.   Comparison of the actuarial LC and KMLC between the HR BCC vs non-HR BCC cohorts were performed using log-rank statistical methods.

High risk histology are defined as Infiltrative, Micronodular, Morpheaform, and Sclerosing subtype of BCCs. Non- HR BCC histology included superficial, nodular, or not otherwise specified (NOS) subtypes.

This study has been determined to be exempt by WCG-IRB under 45 CFR § 46.104(d)(4), because the research involves the use of identifiable information which is recorded by the investigator in such a manner that the identity of the human subjects cannot readily be ascertained directly or through identifiers linked to the subjects, the investigator does not contact the subjects, and the investigator will not re-identify subjects.

3. Results

Patient/Lesion characteristics:

Between 2016-2023, 394 high risk (HR) BCC and 8,130 non-HR BCC lesions were treated with IGSRT.

Table 1 summarizes the patient age and gender revealing a slight predominance of males (55.1%) overall however, there were slightly more females proportionally in the HR group. Mean age of patients was 72.3 ranging from 19.7 to 104.5.

Table 1. Patient Characteristics Tables *.

AGE (YEARS) AT FIRST TREATMENT						
ALL	**Mean**	**(min-max)**	**HR Mean**	**(min-max)**	**Non-HR**	**Mean (min-max)**
n =5685	72.3	(19.7-104.5)	n = 321 72.7	(40.0-97.5)	n =5715	71.9 (19.7-104.5)
GENDER						
	ALL		**HR**		**non HR**	
Male	3353		180		3173	
Female	2727		193		2534	
Total	6080		373		5707	

* Not all patient genders and ages were available.

Table 2 demonstrates the anatomic distributions of NMSC lesions separated by risk groups. As expected, the most common sites of BCC lesions were on the head and neck(H&N). There were more HR BCCs occurring in the H&N region in comparison to the non-HR BCC cohort (85% vs 72%).

Table 2. Anatomic distribution of NMSC lesions.

	HR BCC	NON-HR BCC
Head and neck (H&N)	**335/393 (85.24%)**	**5969/7893 (71.93%)**
H&N sublocation		
Ear	62/393 (15.78%)	652/7893 (8.26%)
Cheek	5/393 (1.27%)	1210/7893 (15.33%)
Nose	152/393 (38.68%	2247/7893 (26.47%)
Cutaneous lip	12/393 (3.05%)	271/7893 (3.43%)
Mucosal lip	1/393 (0.25%)	14/7893 (0.18%)
Forehead	33/393 (8.40%)	749/7893 (9.45%)
Temple	9/393 (2.29%)	247/7893 (3.13%)
Scalp	12/292 (3.05%)	221/7893 (2.80%)
Neck	8/393 (2.04%)	361/7893 (4.57%)
Extremities	**28/393 (7.12%)**	**859/7893 (10.88%)**
*Extremities sublocation**		
Hand	4/393 (1.02%)	32/7893 (0.41%)
Trunk	**15/393 (3.82%)**	**425/7893 (5.38%)**
Trunk sublocation		
Chest	5/393 (1.27%)	114/7893 (1.44%)
Back	10/393 (2.54%)	245/7893 (3.10%)
Shoulder	**3/393 (0.76%)**	**249/7893 (3.15%)**

* Not all lesion sublocations are shown.

Table 3 summarizes the different pathologic subtypes of high risk and non high risk BCC cohorts. Infiltrative (60.6%) and sclerosing (19.3%) were the most common subtypes for the high risk BCC group. The most common pathology subtypes for the non high risk BCC group were nodular (60.9%) and not otherwise specified (27.0%) histology.

Table 3. Pathology Subtypes[a] of HR BCC and non-HR BCC.

HR BCC				NON-HR BCC		
MN	SCL	INF	MOR	NOS	SUP	NOD
67/393 (17.1%)	76/393 (19.3%)	238/393 (60.6%)	12/393 (3.1%)	2185/8113 (27.0%)	977/8113 (12.0%)	4938/8113 (60.9%)

[a]MN = Micronodular; SCL = Sclerosing; INF = Infiltrating; MOR = Morpheaform; NOS = Not otherwise specified; SUP = Superficial; NOD = Nodular.

Table 4 summarizes high risk and non-high risk BCC lesion diameter and depth. The mean diameter and depths of HR vs non-HR BCCs were similar with mean diameter slightly higher for the HR group (1.37cm) vs the non HR BCC subset (1.26cm). Mean depth recorded by high resolution dermal ultrasound (HRDUS) was greater in the HR cohort (1.59mm) compared to the non-HR cohort (1.38mm). Similarly, the median depth for the HR cohort (1.5mm) was higher vs the non-HR cohort (1.3 mm).

Table 4. BCC initial lesion sizes.

BCC Subcategories	HR BCC	NON-HR BCC
Lesion diameter (cm) at start	**n=391**	**n=8023**
Mean ± SD	1.37 ± 0.96	1.26 ± 0.84
Range	0.30-8.0	0.0-10.5
Median	1.0	1.0
BCC lesion depth (mm) at start	**n=382**	**n=7785**
Mean ± SD	1.59 ± 0.61	1.38 ± 0.52
Range	0.31-4.25	0.0-4.82
Median	1.5	1.3

Table 5 illustrates the tumor stage (based on AJCC 8th edition applied to all body locations rather than just the H&N region to be consistent) separated by high risk and non high risk BCC lesions. The HR BCC cohort had slightly higher proportion of stage II and III lesions compared to the non-HR cohort (22.8% vs 17.5%) whereas the non-HR cohort had a slightly higher proportion of stage I lesions compared to the HR cohort (81.2% vs 76.1%). Of note, there were likely minor errors in staging with 1 lesion in the HR cohort and 9 lesions in the non-HR cohort misclassified as stage 0. Staging discrepancies were not altered in the dataset to maintain the integrity of the data.

Table 5. Stage of NMSC lesions.

	HR BCC	NON-HR BCC
Stage	**n (%)**	**n (%)**
0	1 (0.25)	9 (0.11)
I (0 to <2 cm)	300 (76.14)	6599 (81.21)
II (2 to <4 cm)	79 (20.05)	1320 (16.24)
III (≥ 4 cm)	11 (2.79)	99 (1.22)
Unspecified	3 (0.76)	99 (1.22)
Total	394 (100)	8126 (100)

Table 6 summarizes the total fractions of treatments, total treatment dose, duration of treatment, and duration of follow up separated by the HR vs non-HR cohort. The total treatment fractions were the same amongst the 2 groups with a slightly higher total doses given to the HR BCC group (5524.8 cGy) vs the non-HR BCC group (5394.9 cGy). High risk lesions were treated for an average of 7.2 weeks and had an average follow up interval of 78.8 weeks. Non high risk lesions were treated for an average of 6.9 weeks with an average follow up interval of 98.8 weeks.

Table 6. Total number of treatment fractions, dose, duration, and follow-up interval.

Characteristic	Statistic	HR BCC	NON-HR BCC
Total number of fractions	N	394	8128
	Mean ± SD	20.27 ± 0.91	20.04 ± 1.23
	Range	13.0-25.0	12.0-32.0
	Median	20	20
Total treatment dose (cGy)	N	394	8129
	Mean ± SD	5524.80 ± 229.78	5394.92 ± 241.01
	Range	4453.35-6760.47	3715.95-7363.68
	Median	5507.04	5427
Duration of treatment (weeks)	N	394	8124
	Mean ± SD	7.15 ± 2.03	6.89 ± 2.18
	Range	0.14-24.28	0.14-61.71
	Median	6.64	6.57
Duration of follow-up (weeks)	N	394	8129
	Mean ± SD	78.79 ± 68.94	98.83 ± 87.99
	Range	0.14-362.85	0.00-391.00
	Median	58.36	76.00

Table 7 summarizes the energies that the lesions were treated with (50kV, 70kV, or 100 kV exclusively, or mixed) Lesions that were treated with more than one energy during the treatment course were termed as "mixed".   Approximately 3% of high risk lesions and 11% of non-high risk lesions were treated with a mix of two or more energies.

Table 7. NMSC lesion treatment by energy.

	HR BCC	Non-HR BCC
Energy (kV)	N = 394	N = 8123
50	21 (5.33%)	1468 (18.07%)
70	171 (44.40%)	4279 (52.68%)
100	190 (48.22%)	1484 (18.27%)
Mixed	12 (3.05%)	892 (10.98%)
Total*	394 (100%)	8123 (100%)

*Some lesions did not have energies recorded.

Table 8 highlights the safety profile of IGSRT treatment for both groups. There were no reports of grade 4 toxicity in the HR group and only 3 lesions from more than 5000 cases with grade 4 toxicity in the non-HR group. Grade 3 toxicity was also rare with 1.4% in the HR and 3.7% in non-HR group. This indicates that IGSRT treatment appeared safe and well tolerated and similar in both groups.

Table 8. Toxicity—by risk group based on RTOG criteria.

Characteristic	Grade	Description	HR BCC (*n* = 283)	NON HR (*n* = 5009)
Highest RTOG toxicity grade	1	Follicular, faint, or dull erythema; epilation; dry desquamation; decreased sweating	162 (57.24%)	3196 (63.81%)
	2	Tender or bright erythema, patchy moist desquamation; moderate edema	117 (41.34%)	1627 (32.48%)
	3	Confluent, moist desquamation other than skin folds; pitting edema	4 (1.41%)	183 (3.65%)
	4	Ulceration, hemorrhage, necrosis	0 (0.00%)	3 (0.09%)

RTOG (Radiation Treatment Oncology Group) (Not all lesions have documented scores).

3.1. Lesion Local Control

With a mean follow up of over 1.5 years in the HR cohort and almost 2 years in the non-HR group (going well past 5 years in a substantial number of lesions), there were no failures/recurrences in the HR BCC cohort w 100% local control.   In the non-HR BCC cohort there were 33 failures.

Actuarial Local Control at 2 and 5 years:

An actuarial 2 yr LC of 99.7% and 5 yr actuarial LC of 99.2% was achieved in the non-HR group. The actuarial LC rates for the HR group were 100% at both 2 and 5 years. There was no statistical difference between the 2 cohorts' actuarial LC rates on log-rank testing (p= 0.233) (Figure 1).

Figure 1. Actuarial Local Control at 2 and 5 Years for non-High Risk BCC (red line) and high risk BCC (blue line). The graph demonstrates high rates of local control with actuarial 2 year local control of 99.72% and 5 year actuarial local control of 99.19% in the non-high risk cohort and actuarial local control of 100% at 2 and 5 years for the high risk cohort. The log rank test revealed a p-value of 0.237 indicating no statistically significant difference in local control rates between the two groups.

Kaplan-Meier Local Control at 2 and 5 Years:

The non-high risk 2 yr KM LC rate was 99.5%, and the 5 yr KM LC rate was 99.2%. The Kaplan-Meier analysis shows 2 and 5 yr LC of 100% for the high risk subtypes. Statistical analysis using the log-rank test revealed no significant difference (p = 0.233) in local control rates between the two cohorts (Figure 2).

Figure 2. Kaplan-Meier local control curves at 2 and 5 years for non-high risk BCC (red line) and high risk BCC (black line). Kaplan-Meier local control at 2 and 5 years is 99.5% and 99.2% for the non-high risk cohort and 100% at 2 and 5 years for the high risk cohort. The log rank test revealed a p-value of 0.237 indicating no statistically significant difference in local control rates between the two groups.

4. Discussion

This paper presents a comprehensive analysis of superficial radiotherapy (ultrasound guided) treatment on a large reported series of pure BCC patients in the United States, separated by a high risk cohort consisting of 394 lesions of infiltrative, morpheaform, micronodular and sclerosing subtypes and a non-high risk BCC cohort (nodular, superficial and NOS subtypes) comprising of 8130 lesions. Both cohorts underwent a similar treatment regimen with doses and energies using HRDUS guided superficial radiation therapy (commercially and commonly referred to as IGSRT) following a previously published regimen (Ladd-Yu protocol) [12]. The HR BCC cohort showed 100% 2 and 5 year KM LC which was minimally (and non statistically significantly) higher than the non-HR BCC subgroup (99.5% and 99.2% KM LC) at 2 and 5 years, respectively.

Both HR and non HR groups had low toxicity of treatment with the regimen used showing RTOG toxicity generally limited to grades of 1 and 2, and rare instances of RTOG 3 and 4 toxicity.

These results show that high risk histology subtypes of BCC are indeed radiosensitive using SRT combined w HRDUS guidance. In fact, these aggressive BCC subtypes may actually be paradoxically more radiosensitive when compared to standard/non-aggressive BCC subtypes. Although the number of HR cases are much lower than the non-HR BCC group, the authors feel that there are substantially sufficient numbers to justify the validity of the results and conclusions. This observation may actually be consistent with other high grade tumor subtypes where a similar paradoxically higher radiosensitivity and initial complete response rate occurs in comparison to lower grade cells such as in Bladder cancers and lymphomas, etc [19]. Albeit in these other decidedly more life threatening cancers with their tendency for distant or nodal metastases, the initial response

may not translate to better ultimate outcome.   We feel that for the typically local only behavior of BCCs, that the radiosensitivity and complete response rate does indeed translate to ultimate long term local control or "cure" (a term many dermatologists like to use for BCCs and other early stage NMSC) of the target lesion, regardless of aggressiveness.

The LC differences between the 2 groups are small (<1%) by statistical analyses with both cohorts showing outstanding LC out past 5 years and no statistically significant difference in lesion local control rates by log rank analysis. This >99% LC in all subtypes of BCCs establishes that the relatively new modality of IGSRT is appropriate for all stage I-II and selected stage III BCCs regardless of subtype.

Debunking Myths of radioresistence of HR BCC

These results contribute to debunking the myth that radiation therapy is ineffective or less effective for high risk BCCs. Our analysis shows an equivalent or actually lower failure rate (of 0%) of the HR BCC cohort compared to the non-high risk cohort (at 0.5-0.8% failure).

The most obvious explanation for this improvement is the new imaging ability of IGSRT over traditional non-image guided radiotherapy modalities leading to improved energy and dose selection or modification.   In 2 recent studies using logistic-regression analysis and meta-analysis, LC in the treatment of NMSC using IGSRT in comparison to non-image guided external radiation modalities (superficial radiation therapy (SRT) or external beam radiation therapy (XRT including electron beam or photon radiotherapy)) have been shown to be superior and achieving statistically improved LC [14,15] and were attributed to the image guidance factor. Whereas previously, the use of RT may not have been recommended for high risk BCCs due to potentially higher recurrence rates, the advent of HRDUS in combination with SRT allow more precision to be directed to the full depth of the tumor and ushers in an era of modern more exacting targeting of radiation beams that appears to be associated with higher success rates rivaling that of surgical interventions such as MMS and present a valuable alternative treatment option especially for those who are not ideal candidates for surgical management.   This paradigm shifting development uses the HRUS which has high correlation with depth of tumor involvement [20] and is useful not only in pre-treatment planning but also in evaluation during the midst of treatment as well as for following the lesion post treatment at the post therapy area in both scenarios of surgical and non-surgical (including definitive radiotherapeutic) treatment approaches. The imaging can give information to help in treatment modification/adaptation and direct potential salvage therapy selection post therapy. HRDUS may also be helpful to help differentiate the aggressive subtypes of BCC versus non-aggressive subtypes based on the echogenicity of the ultrasound findings [20]. Further discussion of the use of HRUS is beyond the scope of this paper and may be a good subject for future publications.   The utility of HRDUS in surgical NMSC scenarios may benefit from further research endeavors.

Based on the results of this study, IGSRT is indeed a good option to eradicate all early stage and select stage III BCC including HR histologies and may be preferred over surgical excision/MMS in select situations. These situations include patients with surgical fatigue, lesions in cosmetically/functionally sensitive locations, poor performance status subjects on anticoagulation, or those who cannot tolerate a prolonged surgical procedures requiring patient to remain still for extended periods of time, or those who decline surgery.

By examining the outcomes of these cases, this paper challenges the prevailing notions about the management of high risk and non-risk BCCs and provides evidence that may change treatment perspectives and future guidelines.   A paradigm shift may be advocated for how high risk BCC is approached, moving away from previous notions of surgical only treatments to a more customized evidence-based approach that is also non-surgical.

As the prevalence of skin cancer continues to expand, such advancements are critical in the evolving landscape of cancer care ensuring that patients, in consultation with their dermatology and/or radiation/ oncology providers, make a patient centered, informed decision with regard to selection of the treatment modalities best suited for his or her specific situation to maximize optimal

outcomes as well as assuring safety by minimizing short term and long term toxicity. This will allow the patient to achieve the best quality of life, both functionally and cosmetically.

4.1. Limitations

A number of practices may have excluded these high risk BCCs categorically and steered these patients to Mohs after discussion. Others did not exclude any histological subtypes.   The category of not otherwise specified BCCs may have certain BCCs that may have elements of high risk features that were simply not reported and perhaps might have accounted for some of its failures.

Competing risks of death was not accounted for however, we feel that BCC typically does not affect mortality, thus we felt exclusions based on this was not necessary and thus this was not done in this paper.

5. Conclusion

IGSRT achieves high success rates in all subtypes of locally limited stage I-III BCC in retrospective review on about 8,500 cases in the USA.

HR BCC subtypes may actually be paradoxically more radiosensitive than or at least equivalent in radiosensitivity to other more common "non-aggressive" BCC subtypes.

There are no contraindications to using RT in the form of SRT combined w HRDUS (commonly called IGSRT) for high risk subtypes of BCCs. In fact, in patients with any subtype of BCC, IGSRT may be preferential over excision/MMS if the patient is a poor surgical candidate, has lesions in cosmetically/functionally sensitive locations or if the patient prefers a non-surgical approach.

Conflict of Interest: The first author has received research, speaking and/or consulting support from a commercial company. He has served on an advisory board for another commercial company previously unrelated to this research. The other authors have no conflicts of interest to disclose.

Availability of data and material: The data underlying this article will be shared on reasonable request to the corresponding author for at least 1 year.

Ethic approvals/IRB: This study has been determined to be exempt by WCG-IRB under 45 CFR § 46.104(d)(4), because the research involves the use of identifiable information which is recorded by the investigator in such a manner that the identity of the human subjects cannot readily be ascertained directly or through identifiers linked to the subjects, the investigator does not contact the subjects, and the investigator will not re-identify subjects.

Consent to participate: Not applicable for this study (all patients signed informed consent for the initial treatment).

Consent for publication: Not applicable

Code availability: Not applicable

Author contributions: All authors have contributed to the manuscript and approved the final submitted version of the manuscript. Lio Yu- Conceptualization, methodology, data collection and curation, supervision, data and statistics verification, writing- original draft, review and editing. Michael Kaczmarski- data collection, data and statistics verification, tables and figures, writing- original draft, review and editing. Peyton Harris-

References

1. Katalinic A, Kunze U, Schäfer T. Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol. 2003 Dec;149(6):1200–6.

2. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010 Mar;146(3):283–7.

3. Puig S, Berrocal A. Management of high-risk and advanced basal cell carcinoma. Clin Transl Oncol. 2015 Jul 1;17(7):497–503.

4. Rubin Adam I., Chen Elbert H., Ratner Désirée. Basal-Cell Carcinoma. New England Journal of Medicine. 2005;353(21):2262–9.

5. Marghoob A, Kopf AW, Bart RS, Sanfilippo L, Silverman MK, Lee P, et al. Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma. Journal of the American Academy of Dermatology. 1993 Jan 1;28(1):22–8.

6. Tanese K. Diagnosis and Management of Basal Cell Carcinoma. Curr Treat Options Oncol. 2019 Feb 11;20(2):13.

7. Paolino G, Donati M, Didona D, Mercuri SR, Cantisani C. Histology of Non-Melanoma Skin Cancers: An Update. Biomedicines. 2017 Dec 20;5(4):71.

8. Bichakjian C, Armstrong A, Baum C, Bordeaux JS, Brown M, Busam KJ, et al. Guidelines of care for the management of basal cell carcinoma. Journal of the American Academy of Dermatology. 2018 Mar 1;78(3):540–59.

9. Nguyen TH, Ho DQD. Nonmelanoma skin cancer. Curr Treat Options in Oncol. 2002 Jun 1;3(3):193–203.

10. Kappelin J, Nielsen K, Nilsson F, Bjellerup M, Ahnlide I. Surgical treatment of basal cell carcinoma: a case series on factors influencing the risk of an incomplete primary excision. Journal of the European Academy of Dermatology and Venereology. 2020 Mar 2; 34(11):2518–25.

11. Durmus Ucar AN, Durmus Kocaaslan FN, Salman A, Demirkesen C, Erdem Bayram F, Bayramicli M. Margin-Controlled, Staged Surgical Excision in the Treatment of High-Risk Basal Cell Carcinomas of the Head and Neck Region. J Cutan Med Surg. 2019 May;23(3):258–64.

12. Yu L, Oh C, Shea CR. The Treatment of Non-Melanoma Skin Cancer with Image-Guided Superficial Radiation Therapy: An Analysis of 2917 Invasive and In Situ Keratinocytic Carcinoma Lesions. Oncol Ther. 2021 Feb 5; 9(1):153–66.

13. Tran A, Moloney M, Kaczmarski P, Zheng S, Desai A, Desai T, et al. Analysis of image-guided superficial radiation therapy (IGSRT) on the treatment of early-stage non-melanoma skin cancer (NMSC) in the outpatient dermatology setting. J Cancer Res Clin Oncol. 2023; 149(9):6283–91.

12 of 12

14. Yu L, Moloney M, Tran A, Zheng S, Rogers J. Local control comparison of early-stage non-melanoma skin Cancer (NMSC) treated by superficial radiotherapy (SRT) and external beam radiotherapy (XRT) with and without dermal image guidance: a meta-analysis. Discov Oncol. 2022 Nov 21;13(1):129.

15. Yu L, Moloney M, Zheng S, Rogers J. High resolution dermal ultrasound (US) combined with superficial radiation therapy (SRT) versus non-image guided SRT or external beam radiotherapy (XRT) in early-stage epithelial cancer: a comparison of studies. BMC Cancer. 2023 Jan 28;23(1):98.

16. McClure EM, Cockerell CJ, Hammond S, Marienberg ES, et al. Image-Guided Radiation Therapy Is Equally Effective for Basal and Squamous Cell Carcinoma. Dermatopathology (Basel). 2024;11(4):315-329.

17. Farberg AS, Heysek RV, Haber R, et al. Freedom from Recurrence across Age in Non-Melanoma Skin Cancer Treated with Image-Guided Superficial Radiation Therapy. Geriatrics. 2024;9(5):114.

18. Agha R, Heysek RV, Vasily DB, et al. Image-Guided Superficial Radiation Therapy for Basal and Squamous Cell Carcinomas Produces Excellent Freedom from Recurrence Independent of Risk Factors. Journal of Clinical Medicine. 2024;13(19):5835.

19. Kimball AS, Webb TJ. The Roles of Radiotherapy and Immunotherapy for the Treatment of Lymphoma. Mol Cell Pharmacol. 2013 Jan 1;5(1):27–38.

20. Laverde-Saad A, Simard A, Nassim D, Jfri A, Alajmi A, O'Brien E, et al. Performance of Ultrasound for Identifying Morphological Characteristics and Thickness of Cutaneous Basal Cell Carcinoma: A Systematic Review. Dermatology. 2022;238(4):692–710.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.